Genomic Data Standardization

1/ You think clinical trial genomics is simple: compare pre‐ vs post‐treatment RNA‐seq. But even getting clean metadata? That’s a war. 2/ Pre-treatment isn’t just "before drug": Samples taken >30 days pre-first-dose risk capturing pre-malignancy or prior therapy effects (not true baseline). True baseline: ≤30 days pre-first-dose, with no active treatment. Otherwise, it’s tumor evolution. 3/ Post-treatment ambiguity: Anchoring to "last dose" (e.g., 30 days post) is common BUT: If relapse occurs before 30 days, relapse date overrides. No universal standard—trial protocols define this! 4/ Age metadata pitfalls: Use diagnosis date, not biopsy date. Why? Biopsies can lag diagnosis → misaligns with molecular clocks. Months matter: Metastatic timing shifts survival analyses. 5/ Relapse timing is biology: Primary refractory: Progression during therapy. Early relapse: ≤24 months post-diagnosis (aggressive clones). Late relapse: >24 months (new clones, better prognosis). → Each has distinct drivers. 6/ Stratifying by mutations? Mixing exome kits = coverage bias (e.g., Pan-Cancer vs. IDT kits). Solution: Batch-correct or require uniform platforms. False signals haunt 43% of multi-center studies. 7/ Tumor origin shifts: Late relapses? 60% are clonally unrelated to primary tumors. Check sample site: Same tissue? If not, biology isn’t comparable. 8/ Missing dates: "Ongoing" flags (e.g., --ONGO in CDASH) are essential. Blanks ≠ "unknown"—they break survival models. → Always map to SDTM standards. 9/ Why standards save you: CDASH/SDTM are used in industry trials (e.g., FDA submissions). Academic neglect = 300+ hours manually fixing dates/units. → Adopt standards or drown in chaos. 10/ You’re not just analyzing variants. You’re wrestling: "Is this true baseline?" "Is progression measured by RECIST or biopsy?" → Definitions win or lose trials. 11/ Key takeaways: Metadata = your foundation, not glue. Pre/post-treatment timing = biological truth. Relapse categories = distinct diseases. Standards exist—use them or invent nothing. 12/ Clinical genomics isn’t clean code—it’s biography. Stop asking “Did you run DESeq2?” Ask: “Who was treated, how, when, and why?” I hope you've found this post helpful. Follow me for more. Subscribe to my FREE newsletter chatomics to learn bioinformatics https://lnkd.in/erw83Svn

Plant breeding generates massive datasets, but most remain locked in silos due to trust barriers and technical incompatibilities that slow innovation. Our new study introduces "Data cohorts" (structured packages of interoperable breeding data) paired with a Data Trustee Platform that enables federated sharing while protecting proprietary interests. By implementing FAIR principles from the start and using dynamic licensing with secure analysis environments, we show how genomic prediction accuracy doubled when aggregating previously isolated datasets. The key? Standardized metadata, common genotype references, and quality metrics that let breeders access relevant data without compromising competitive advantage. When data flows freely but safely, everyone's breeding programs get stronger and innovation accelerates. https://lnkd.in/dq2dJUHk

Important evaluation study just published by Friends of Cancer Research which assesses baseline ctDNA levels across 5 cancer types (NSCLC, breast, bladder, prostate, and HNSCC) at different stages, using 8 commercially available assays. The goal of this effort was to see how well ctDNA functions as a potential early indicator of treatment response across various cancer types & stages, and what type of data harmonization efforts might be needed in that context. Here are some of the key takeaways: 1. ctDNA Baseline levels were consistently detectable in late-stage cancers. 2. For early-stage lung cancer, ctDNA levels varied more between different assays, pointing towards tests themselves (their design and how they were conducted) and how technical aspects may affect the results. 3. Need for standardized data: The way assays identified mutations and filtered out certain genetic background noise differed between them. To make reliable comparisons in the future, researchers need to agree on standard ways to collect and report ctDNA data, including assay details and clinical information about the patients. 3. Real-world data limitations: Using #realworlddata from healthcare settings can be helpful, but it also has drawbacks. In this study, there was often missing information about patients' medical history and the timing of their ctDNA test relative to diagnosis. Having more complete data would allow for more accurate comparisons. Overall, this study highlights the potential of #ctDNA as a biomarker, especially in later stages. However, for ctDNA to be a reliable early indicator of treatment response, researchers need to standardize how they collect and analyze data. https://lnkd.in/dHmxRP-v #precisiononcology #harmonization #ctDNA #biomarker

🔬 Skin Explorer: Unlocking the Single Cell Atlas of Human Skin Multiple omics technologies such as genomics, transcriptomics, proteomics and epigenomics are now available to study human skin in unprecedented detail. Yet much of the data remains scattered across publications, generated with different pipelines and naming conventions, making direct comparison and reuse extremely difficult. This lack of harmonization limits the potential to translate these datasets into real insights for skin biology, dermatology and skincare innovation. A new paper "Skin Explorer: an interactive single cell RNA seq resource for healthy human skin" https://lnkd.in/eHzUbAcG in Journal of Investigative Dermatology introduces Skin Explorer, a harmonized, interactive resource that integrates 24 scRNA seq datasets from 146 healthy human skin donors, covering more than 637,000 cells. 🔑 Key insights: ✅ 24 independent datasets reanalyzed with a unified pipeline, harmonized gene names and standardized metadata. ✅ Interactive tool Skin Explorer https://lnkd.in/ebCiNtYP enables visualization by gene, cell type, sex or body site, and generates publication ready figures. ✅ Dynamic database designed to expand as new skin datasets are integrated. 📌 Examples of use : -Pigmentation: querying SOX10 reveals Schwann cell and melanocyte specific expression patterns, providing insights into pathways that regulate skin tone and UV response. -Hair biology: discovery of a COCH+ fibroblast subpopulation linked to hair follicles could inform studies on scalp health, hair density and follicle targeted treatments. -Comparative biology: side by side dataset comparisons allow researchers to assess age, sex or site specific differences, critical for designing personalized skincare interventions. 💡 Why it matters for beauty biotech: This resource enables high resolution exploration of the molecular diversity of human skin. For companies and researchers developing skincare actives, diagnostics or personalized interventions, Skin Explorer provides a robust reference to: -Benchmark cell type specific responses (fibroblasts, keratinocytes, melanocytes). -Validate biomarkers for skin aging, pigmentation, inflammation or wound healing. -Design transcriptomic studies with harmonized context across multiple cohorts. By making skin scRNA seq data accessible, standardized and interactive, Skin Explorer represents a step toward precision dermatology and scientifically rigorous skincare innovation. 📊 Resources for deeper exploration: Code: https://lnkd.in/eE5shwXC Data repository: https://lnkd.in/ekGSUbva Interactive tool: https://lnkd.in/ebCiNtYP #beautybiotech #skingenomics #precisiondermatology #skincareinnovation #bioinformatics #skintech